4//SEC Filing
Boyer David W. 4
Accession 0000914475-24-000069
CIK 0000914475other
Filed
Feb 14, 7:00 PM ET
Accepted
Feb 15, 5:33 PM ET
Size
12.4 KB
Accession
0000914475-24-000069
Insider Transaction Report
Form 4
Boyer David W.
Chief Corp. Affairs Officer
Transactions
- Sale
Common Stock
2024-02-13$133.10/sh−955$127,106→ 5,751 total - Sale
Common Stock
2024-02-13$133.05/sh−856$113,889→ 4,895 total - Award
Stock Option
2024-02-13+30,977→ 30,977 totalExercise: $133.84Exp: 2034-02-13→ Common Stock (30,977 underlying) - Award
Restricted Stock Unit
2024-02-13+6,165→ 6,165 total→ Common Stock (6,165 underlying)
Footnotes (7)
- [F1]Sale of 955 shares of common stock issued upon vesting of 1,811 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (856) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.88. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F4]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F5]Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
- [F6]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
- [F7]The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028.
Documents
Issuer
NEUROCRINE BIOSCIENCES INC
CIK 0000914475
Entity typeother
Related Parties
1- filerCIK 0001909817
Filing Metadata
- Form type
- 4
- Filed
- Feb 14, 7:00 PM ET
- Accepted
- Feb 15, 5:33 PM ET
- Size
- 12.4 KB